share_log

3: Initial statement of beneficial ownership of securities-Director Shoemaker Stephen H

3: Initial statement of beneficial ownership of securities-Director Shoemaker Stephen H

3:首次持股声明-董事 Shoemaker Stephen H
美股SEC公告 ·  12/11 05:36

Moomoo AI 已提取核心信息

Stephen H. Shoemaker has been appointed as a Director of 180 Life Sciences Corp (ATNF) effective December 3, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating Shoemaker's initial statement of beneficial ownership of securities.The filing reveals that Shoemaker currently holds no beneficial ownership of any securities in the company, including both non-derivative and derivative securities. His address is listed as 3000 El Camino Real, Bldg. 4 Suite 200, Palo Alto, CA 94306.The Form 3 was signed by Shoemaker on December 10, 2024, a week after the event requiring the statement. As a director, Shoemaker will play a key role in the company's governance and strategic decision-making processes.
Stephen H. Shoemaker has been appointed as a Director of 180 Life Sciences Corp (ATNF) effective December 3, 2024. This information was disclosed in a Form 3 filing with the United States Securities and Exchange Commission, indicating Shoemaker's initial statement of beneficial ownership of securities.The filing reveals that Shoemaker currently holds no beneficial ownership of any securities in the company, including both non-derivative and derivative securities. His address is listed as 3000 El Camino Real, Bldg. 4 Suite 200, Palo Alto, CA 94306.The Form 3 was signed by Shoemaker on December 10, 2024, a week after the event requiring the statement. As a director, Shoemaker will play a key role in the company's governance and strategic decision-making processes.
史蒂芬·H·舒梅克已被任命为180生命科学公司(ATNF)的董事,任职生效日期为2024年12月3日。此信息通过向美国证券交易委员会提交的Form 3文件披露,表明舒梅克的首次证券实益权益声明。该文件显示,舒梅克目前在公司没有任何证券的实益权益,包括非衍生证券和衍生证券。他的地址为加利福尼亚州帕洛阿尔托市埃尔卡米诺_REAL大街3000号,4号楼200室,邮政编码94306。Form 3于2024年12月10日由舒梅克签署,距要求声明的事件发生一周。在担任董事期间,舒梅克将在公司的治理和战略决策过程中发挥关键作用。
史蒂芬·H·舒梅克已被任命为180生命科学公司(ATNF)的董事,任职生效日期为2024年12月3日。此信息通过向美国证券交易委员会提交的Form 3文件披露,表明舒梅克的首次证券实益权益声明。该文件显示,舒梅克目前在公司没有任何证券的实益权益,包括非衍生证券和衍生证券。他的地址为加利福尼亚州帕洛阿尔托市埃尔卡米诺_REAL大街3000号,4号楼200室,邮政编码94306。Form 3于2024年12月10日由舒梅克签署,距要求声明的事件发生一周。在担任董事期间,舒梅克将在公司的治理和战略决策过程中发挥关键作用。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息